📊 VANI Key Takeaways
Is Vivani Medical, Inc. (VANI) a Good Investment?
Vivani Medical is facing imminent liquidity crisis with zero reported revenue and negative operating cash flow of $24.3M annually. At current burn rates, the company will exhaust its $16.2M cash reserves in under 8 months with no demonstrated commercialization path or meaningful business traction.
Why Buy Vivani Medical, Inc. Stock? VANI Key Strengths
- Maintains positive current ratio of 2.71x providing short-term liquidity cushion
- Carries no long-term debt, eliminating debt service obligations
- Holds $16.2M in cash providing near-term operational runway
VANI Stock Risks: Vivani Medical, Inc. Investment Risks
- Zero revenue generation indicates fundamental business failure or complete lack of market commercialization
- Negative operating cash flow of $24.3M annually will deplete cash reserves within 8-10 months creating existential solvency threat
- Negative ROE of -169.2% and ROA of -67.5% demonstrate severe shareholder value destruction
- Operating losses of $27.6M annually with no identified path to profitability or breakeven
Key Metrics to Watch
- Quarterly revenue generation and evidence of commercial traction
- Monthly cash burn rate and cash runway until depletion
- Operating expense reduction and timeline to cash flow breakeven
Vivani Medical, Inc. (VANI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.71x current ratio provides a solid financial cushion.
VANI Profit Margin, ROE & Profitability Analysis
VANI vs Healthcare Sector: How Vivani Medical, Inc. Compares
How Vivani Medical, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Vivani Medical, Inc. Stock Overvalued? VANI Valuation Analysis 2026
Based on fundamental analysis, Vivani Medical, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Vivani Medical, Inc. Balance Sheet: VANI Debt, Cash & Liquidity
VANI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Vivani Medical, Inc.'s revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $-0.43 indicates the company is currently unprofitable.
VANI Revenue Growth, EPS Growth & YoY Performance
VANI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | N/A | -$5.4M | $-0.10 |
| Q1 2025 | N/A | -$6.0M | $-0.11 |
| Q3 2024 | N/A | -$5.4M | $-0.11 |
| Q2 2024 | N/A | -$5.4M | $-0.10 |
| Q2 2021 | N/A | -$2.3M | N/A |
| Q3 2020 | $472.0K | -$1.6M | N/A |
| Q2 2020 | $1.3M | -$3.1M | N/A |
| Q1 2020 | $1.1M | -$8.9M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Vivani Medical, Inc. Dividends, Buybacks & Capital Allocation
VANI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Vivani Medical, Inc. (CIK: 0001266806)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VANI
What is the AI rating for VANI?
Vivani Medical, Inc. (VANI) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VANI's key strengths?
Claude: Maintains positive current ratio of 2.71x providing short-term liquidity cushion. Carries no long-term debt, eliminating debt service obligations.
What are the risks of investing in VANI?
Claude: Zero revenue generation indicates fundamental business failure or complete lack of market commercialization. Negative operating cash flow of $24.3M annually will deplete cash reserves within 8-10 months creating existential solvency threat.
What is VANI's revenue and growth?
Vivani Medical, Inc. reported revenue of $0.0.
Does VANI pay dividends?
Vivani Medical, Inc. does not currently pay dividends.
Where can I find VANI SEC filings?
Official SEC filings for Vivani Medical, Inc. (CIK: 0001266806) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VANI's EPS?
Vivani Medical, Inc. has a diluted EPS of $-0.43.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VANI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Vivani Medical, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is VANI stock overvalued or undervalued?
Valuation metrics for VANI: ROE of -169.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy VANI stock in 2026?
Our dual AI analysis gives Vivani Medical, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VANI's free cash flow?
Vivani Medical, Inc.'s operating cash flow is $-24.3M, with capital expenditures of $1.2M.
How does VANI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -169.2% (avg: 15%), current ratio 2.71 (avg: 2).